11.º FORO DE Inmunología Traslacional e INMUNOTERAPIA DEL CÁNCER 19 17:30-18:00 Coffee break. Poster session ❚ Pausa café. Exhibición de pósteres Poster Session II: Cell-based immunotherapies CP-20. IMPROVING NKG2D CAR-T AS A TREATMENT FOR PEDIATRIC CENTRAL NERVOUS SYSTEM TUMORS Laura Clares Villa1, Andrés París Muñoz1, Marta Ibáñez1, Alfonso Navarro1, Carmen Mestre Durán1, Karima Al-Akioui Sanz1, Lidia Pertiñez1, Jordi Minguillón1, María P. Morales2, Domingo F. Barber3, Antonio Rodríguez4, Aurélie Tchoghandjian5, Lucía Fernández1, Antonio Pérez Martínez1 1Instituto de Investigación Hospital Universitario La Paz (IdiPAZ). CNIO Pediatric Onco-Hematology Unit. Centro Nacional de Investigaciones Oncológicas (CNIO). Madrid, Spain. 2Department of Energy, Environment and Health. Instituto de Ciencia de Materiales Madrid (ICMM-CSIC). Madrid, Spain. 3Department of Immunology and Oncology. Centro Nacional de Biotecnología (CNB-CSIC). Madrid, Spain. 4Molecular Biology Department. Universidad Autónoma de Madrid. Madrid, Spain. 5Centre National de la Recherche Scientifique (CNRS). Institut national polytechnique (INP). Institute of Neurophysiopathology. Aix-Marseille University. Marseille, France CP-21. GENE-TARGETED UNIVERSAL ALLOGENEIC GAMMA-DELTA CAR T CELLS FOR CANCER IMMUNOTHERAPY Ángel Ramírez-Fernández1, Álex Dimitri1, Robert Bartoszek1, Gregory M. Chen1, Laura Córdoba-Espejo1, Yuqi Zhou1, John Scholler1, Anne Chew1, Chien-Ting Lin1, Vanessa E. Gonzalez1, Stefan K. Barta2, Julie K. Jadlowsky1, Donald L. Siegel1, Bruce L. Levine1, Gaël Roué3, Marco Ruella1, Michael T. Lotze4, Carl H. June1, James L. Riley1, Joseph A. Fraietta1 1Center for Cellular Immunotherapies. Perelman School of Medicine. University of Pennsylvania. Philadelphia, USA. 2Lymphoma Program. Abramson Cancer Center. University of Pennsylvania. Philadelphia, USA. 3Lymphoma Translational Group. Josep Carreras Leukaemia Research Institute (IJC). Badalona. Barcelona, Spain. 4Hillman Cancer Center. University of Pittsburgh. Pittsburgh, USA CP-22. RAPID AND STABLE CONTROL OVER CD19POS-TUMOR CELLS DRIVES SUPERIOR ANTITUMOR ACTIVITY IN CD22 CAR-T CELLS SECRETING CD19 TCES COMPARED TO CD19/CD22 DUAL CAR- T CELLS Javier Arroyo-Ródenas1, Aida Falgas2, Laura Díez-Alonso3, Alba Martínez-Moreno4, Heleia Roca-Ho1, Francisco J. Gil-Etayo2, Alba Pérez-Pons3, Óscar Aguilar-Sopeña4, Míriam Velasco-Sidro4, Marina Gómez-Rosel1, Beatriz Jiménez-Matías2, Yedra Pacheco3, Clara Bravo-Martín5, Ángel Ramírez-Fernández6, Anais Jiménez-Reinoso7, Belén Blanco1, Pedro Roda-Navarro2, Clara Bueno3, Pablo Menéndez1, Luis Álvarez-Vallina2 1Cancer Immunotherapy Unit (UNICA). Department of Immunology. Hospital Universitario 12 de Octubre. Madrid. 2Immuno-Oncology and Immunotherapy Group. Instituto de Investigación Sanitaria Hospital 12 de Octubre (Imas12). Madrid. 3Hospital Universitario 12 de Octubre. Centro Nacional de Investigaciones Oncológicas (CNIO). Madrid. 4Josep Carreras Leukaemia Research Institute. Badalona, Barcelona. 5Cancer Research Center (IBMCC, USAL-CSIC). Department of Medicine and Cytometry Service (NUCLEUS). Universidad de Salamanca. Salamanca. 6Biomedical Research Institute of Salamanca (IBSAL). Salamanca. 7Department of Immunology, Ophthalmology and ENT. School of Medicine. Universidad Complutense de Madrid. Madrid. CP-23. STAB-T CELLS SECRETING A TCR-BASED TCE TARGETING NY-ESO-1-POSTIVE TUMORS Rodrigo Lázaro-Gorines, Luis Álvarez-Vallina Centro Nacional de Investigaciones Oncológicas (CNIO). Madrid
RkJQdWJsaXNoZXIy OTI4NTYw